Similar to paxalisib, EVT801 has low toxicity profile and is administered orally. Kazia should be able to take the phase I trial into USA, in addition to Europe.
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia Corporate Presentation
Ann: Kazia Corporate Presentation, page-13
-
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity